Back to top
more

Relmada Therapeutics (RLMD)

(Delayed Data from NSDQ)

$3.83 USD

3.83
80,013

+0.13 (3.51%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.83 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate

by Zacks Equity Research

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.

Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More

by Zacks Equity Research

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

by Zacks Equity Research

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.

Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022

by Zacks Equity Research

Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.

Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) lead drug, Firdapse, is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch.

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.

Down 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD)

by Zacks Equity Research

Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Is the Options Market Predicting a Spike in Relmada (RLMD) Stock?

by Zacks Equity Research

Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.

New Strong Sell Stocks for October 23rd

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.